Drug or treatment

Vebreltinib clinical trials

• 8Clinical trials
• 1Country

Newest trials

All recruiting trials (8)

• Vebreltinib plus furmonertinib in EGFR-mutated NSCLC with high PD-L1

  This study tests whether combining vebreltinib with furmonertinib can help people with advanced NSCLC that has EGFR mutations and very high PD-L1 expression.

  Recruiting Phase 1/2 Second Affiliated Hospital of Nanchang University · Nanchang, Jianxi · NCT07655622

• Vebreltinib with Platinum Chemotherapy as First-line Treatment for MET-Overexpressing NSCLC

  This study tests whether adding vebreltinib to platinum-based chemotherapy can help adults with advanced NSCLC that overexpress MET and lack driver mutations respond to treatment as a first option.

  Recruiting Phase 2 Shanghai Chest Hospital · Shanghai, Shanghai Municipality · NCT07549061

• Vebreltinib for advanced or metastatic clear cell sarcoma

  This study will try taking vebreltinib pills twice daily to treat people aged 12 and older with unresectable or metastatic clear cell sarcoma who have at least one measurable tumor.

  Recruiting Phase 2 Second Affiliated Hospital, Zhejiang University, School of Medicine · Hangzhou, Zhejiang · NCT07153887

• Vebreltinib plus furmonertinib for EGFR‑TKI–resistant NSCLC with c‑MET amplification

  This study tests whether giving vebreltinib together with furmonertinib can help people with advanced NSCLC that developed c‑MET amplification after their EGFR‑targeted therapy stopped working.

  Recruiting at 2 sites Phase 1/2 Peking University Cancer Hospital & Institute · Neimeng, Neimeng and 11 other locations · NCT07087223

• Vebreltinib plus platinum-based doublet chemotherapy for MET-positive non-squamous NSCLC

  This trial will test whether adding the oral drug vebreltinib to standard platinum-based doublet chemotherapy helps people with MET-positive, previously untreated locally advanced or metastatic non-squamous NSCLC.

  Recruiting Phase 3 Beijing Pearl Biotechnology Limited Liability Company · Beijing, Beijing Municipality and 1 other locations · NCT06930794

• First-line treatment for advanced lung cancer with specific genetic mutations

  This study is testing a new combination treatment for people with advanced lung cancer that has specific genetic mutations to see if it helps them feel better and live longer.

  Recruiting Phase 2 Avistone Biotechnology Co., Ltd. · Guangzhou, Guangdong · NCT06574347

• Combining Vebreltinib and PLB1004 for advanced lung cancer with specific mutations

  This study is testing a new combination of two drugs, Vebreltinib and PLB1004, to see if they can help people with advanced lung cancer who have certain genetic changes and haven't responded to previous treatments.

  Recruiting Phase 1/2 Avistone Biotechnology Co., Ltd. · Shanghai, Shanghai Municipality · NCT06343064

• Testing PLB1001 in lung cancer patients with a specific mutation

  This study is testing a new drug called PLB1001 to see if it helps people with a specific type of lung cancer that has a MET exon 14 mutation.

  Recruiting Phase 3 Beijing Pearl Biotechnology Limited Liability Company · Guangzhou, Guangdong · NCT05989542

Quick answers

How many clinical trials of Vebreltinib are recruiting right now?

8, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

All of them have sites in China. Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 3, Phase 1/2: 3, Phase 3: 2. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →